Medications covered include glucose-like peptide-1 (GLP-1) receptor agonists, of which liraglutide is FDA approved for the treatment of obesity in the absence of diabetes, as well as other classes of diabetes medications that have weight loss effects including dipeptidyl peptidase-4 (DPP-4) inhibitors, metformin, and sodium-glucose cotransporter 2 (SGLT2) inhibitors. The gene discussed is DPP4; the disease is Obesity.